<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02856594</url>
  </required_header>
  <id_info>
    <org_study_id>2016P000742</org_study_id>
    <secondary_id>1R01AG053582</secondary_id>
    <nct_id>NCT02856594</nct_id>
  </id_info>
  <brief_title>Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep</brief_title>
  <acronym>MINDDS</acronym>
  <official_title>Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS): A Randomized Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine whether, compared with placebo, the nighttime administration of&#xD;
      a intravenous dexmedetomidine is effective at inducing sleep and preventing postoperative&#xD;
      delirium in extubated post-cardiac surgical patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Delirium is an acute brain dysfunction characterized by disturbances in attention, awareness,&#xD;
      and cognition not explained by a preexisting neurocognitive disorder. Although the increased&#xD;
      mortality rates ascribed to delirium remain debatable, delirium remains a leading cause of&#xD;
      preventable morbidity in hospitalized elderly patients. It is also associated with prolonged&#xD;
      hospitalization, prolonged institutionalization, and long-term cognitive deficits. Patients&#xD;
      with pre-existing dementia, such as Alzheimer's disease, are especially vulnerable to&#xD;
      developing delirium. The total healthcare cost attributable to delirium is estimated between&#xD;
      $143 and $152 billion annually. In the United States, delirium occurs in approximately 80% of&#xD;
      critically ill patients admitted to medical/surgical intensive care units (ICU), and 15% of&#xD;
      patients admitted to cardiac surgical (CS) ICU. Most patients diagnosed with delirium also&#xD;
      present with multiple comorbidities (sepsis, multi-organ failure) that significantly confound&#xD;
      our understanding of this disease. Thus, to date, no pharmacological intervention to treat&#xD;
      delirium has been identified.&#xD;
&#xD;
      There is mounting evidence to suggest that sleep deprivation may be a modifiable risk factor&#xD;
      for the development of delirium. Presently, pharmacological treatment with no current&#xD;
      medication (benzodiazepines, antipsychotics) induces natural sleep or reliably reduces the&#xD;
      incidence of delirium. The investigators have found that biomimetic sleep, defined here as&#xD;
      pharmacological induction of rapid eye movement sleep (REM) and non-REM (N1, N2, N3) sleep&#xD;
      states using dexmedetomidine, can now be achieved in humans. The overall objective of this&#xD;
      study is to evaluate the efficacy of biomimetic sleep in reducing the incidence and severity&#xD;
      of delirium in extubated CSICU patients. The investigators will also assess for&#xD;
      peri-operative electroencephalogram biomarkers of delirium, and the association between&#xD;
      delirium and chronic neuroinflammation using positron emission tomography. The MINDDS study&#xD;
      is poised to enable therapeutic and diagnostic discoveries to aid the care of elderly&#xD;
      patients who are at risk for developing postoperative delirium.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 6, 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of delirium</measure>
    <time_frame>Post operative day 1 (24 hours)</time_frame>
    <description>Confusion Assessment Method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU delirium/coma-free days</measure>
    <time_frame>Up until postoperative day 3, or up until postoperative day 7 or discharge for patients who are delirious beyond postoperative day 5</time_frame>
    <description>Confusion Assessment Method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Delirium</measure>
    <time_frame>Up until postoperative day 3, or up until postoperative day 7 or discharge for patients who are delirious beyond postoperative day 5</time_frame>
    <description>Confusion Assessment Method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day, 90-day, and 180-day mortality</measure>
    <time_frame>Up to postoperative day 180 (6 months)</time_frame>
    <description>30-day, 90-day, and 180-day mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Cognitive Status</measure>
    <time_frame>30 days, 90 days, and 180 days postoperatively</time_frame>
    <description>Telephone Montreal Cognitive Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative health related quality of life</measure>
    <time_frame>30 days, 90 days, and 180 days postoperatively</time_frame>
    <description>PROMIS-29 questionnaires</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>from postoperative day 0 until date of hospital discharge (no prespecified length possible)</time_frame>
    <description>Medical Record Review</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Postoperative Delirium</condition>
  <condition>Sleep</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine-induced sleep</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Precedex (Dexmedetomidine) intervention: Intravenous administration of 1mcg/kg over 40 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of normal saline: Intravenous administration of normal saline over 40 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine</description>
    <arm_group_label>Dexmedetomidine-induced sleep</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 60&#xD;
&#xD;
          -  Scheduled for a cardiac surgical procedure with planned post-operative admission to&#xD;
             the CSICU for ≥ 24 hours&#xD;
&#xD;
          -  Scheduled same day surgical admission&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Blind, deafness or the inability to speak English&#xD;
&#xD;
          -  Greater than 2 days of ICU admission in the month preceding the current surgical&#xD;
             procedure&#xD;
&#xD;
          -  Renal and liver failure requiring dialysis or Child-Pugh score &gt; 5&#xD;
&#xD;
          -  Follow-up difficulties (i.e. active substance abuse, psychotic disorder, homelessness)&#xD;
&#xD;
          -  Previous cardiac surgery within 1 year of surgical procedure&#xD;
&#xD;
          -  Allergy to dexmedetomidine&#xD;
&#xD;
          -  Chronic therapy with benzodiazepines and/or antipsychotics&#xD;
&#xD;
          -  Severe deficit due to structural or anoxic brain damage&#xD;
&#xD;
          -  Surgical procedure requiring total circulatory arrest&#xD;
&#xD;
        Objective Drop Criteria&#xD;
&#xD;
          -  Scheduled for a second surgical procedure during hospital stay&#xD;
&#xD;
          -  Post-operative intubation &gt; 12 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Oluwaseun Johnson-Akeju, MD, MMSc</investigator_full_name>
    <investigator_title>Assistant Professor in Anesthesia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

